港股医药类指数及ETF对比

• The report focuses on Hong Kong pharmaceutical indices and ETFs, highlighting the significant tracking scale of indices such as Guozheng Hong Kong Stock Connect Innovative Drugs and Hong Kong Innovative Drugs, with tracking ETF scales of 341.3 billion yuan and 226.4 billion yuan respectively [1][6][7] - Since August 2025, Guozheng Hong Kong Stock Connect Innovative Drugs and Hong Kong Innovative Drugs indices have seen net inflows of 145.1 billion yuan and 81.5 billion yuan respectively, ranking among the top two in terms of net inflows [7][10] - Seven indices focus on the innovative drug sector, with one compiled by Guozheng Index, two by China Securities Index, and four by Hang Seng Index. Indices compiled by the same company show similar compilation schemes and performance, while differences exist between companies. Year-to-date (YTD) returns show China Securities > Guozheng ≈ Hang Seng [7][12] - The industry distribution of indices varies: Guozheng and Hang Seng indices have a higher proportion of pharmaceutical industry, while China Securities indices have a higher proportion of biotechnology and life sciences tools and services [7][13] - Guozheng Hong Kong Stock Connect Innovative Drugs index experienced short-term deviation in September due to individual constituent stock adjustments during the sample adjustment period, but the deviation was corrected within two trading days, and the subsequent operation returned to normal [7][14]